1. Home
  2. ALZN vs SNOA Comparison

ALZN vs SNOA Comparison

Compare ALZN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.22

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$1.15

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALZN
SNOA
Founded
2016
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
4.0M
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
ALZN
SNOA
Price
$1.22
$1.15
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
51.8K
95.6K
Earning Date
03-11-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
22.99
32.26
EPS
N/A
N/A
Revenue
N/A
$19,529,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.68
52 Week Low
$0.84
$0.85
52 Week High
$3.60
$6.92

Technical Indicators

Market Signals
Indicator
ALZN
SNOA
Relative Strength Index (RSI) 56.14 45.78
Support Level $1.03 $1.00
Resistance Level $1.29 $1.25
Average True Range (ATR) 0.07 0.09
MACD 0.01 0.03
Stochastic Oscillator 57.14 46.15

Price Performance

Historical Comparison
ALZN
SNOA

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: